Examining vaccine responses in cancer patients
Vaccine Responses in Cancer
Abramson Cancer Center at Penn Medicine · NCT06605625
This study looks at how well flu, COVID-19, and shingles vaccines work in cancer patients who are getting treatment for their cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine (other) |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT06605625 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the immune responses of cancer patients receiving vaccinations for influenza, SARS-CoV-2, and shingles. It aims to assess how these vaccines perform in individuals undergoing various anti-tumor treatments, as the immunogenicity of vaccinations in this population has not been thoroughly studied. By monitoring the immune responses, the study seeks to provide insights into the effectiveness of these vaccines in cancer patients.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with a cancer diagnosis who are willing to receive the specified vaccinations.
Not a fit: Patients who are allergic to the vaccines or have conditions like HIV or a history of organ transplant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance vaccination strategies for cancer patients, improving their immune responses and overall health outcomes.
How similar studies have performed: While there is limited data on vaccine responses specifically in cancer patients, similar studies have shown varying success in assessing vaccine efficacy in immunocompromised populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adults over age 18 who are able to provide consent, who have a diagnosis of cancer, and are willing to receive the influenza, recombinant shingles, and/or SARS-CoV-2 vaccines. Exclusion Criteria: * allergic to influenza, shingles, and/or SARS-CoV-2 vaccination; have HIV infection; have a history of solid organ or bone marrow transplant.
Where this trial is running
Philadelphia, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: E. John Wherry, PhD — Univeristy of Pennsylvania
- Study coordinator: Sokratis Apostolidis, MD
- Email: sokratis.apostolidis@pennmedicine.upenn.edu
- Phone: 267-584-6653
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Viral Vaccines, influenza